Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10
Published March 19, 2025 · Recall initiated: February 28, 2025
Summary
FDA records drug Class II recall D-0270-2025, published March 19, 2025 and initiated February 28, 2025. Recalling firm: Breckenridge Pharmaceutical, Inc.; Status: Ongoing; Reported quantity: 14,749 bottles.; Lot: Lot#: 240225C, Expiration: 01/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
What to do
Voluntary: Firm initiated · Letter
Get an email if DULOXETINE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DULOXETINE
- Manufacturer
- Breckenridge Pharmaceutical, Inc.
- Distributor
- Nationwide
- Lot
- Lot#: 240225C, Expiration: 01/2027
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDADuloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000June 17, 2026
- FDADuloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles, Rx only, Manufactured. by: TowaJune 17, 2026
- FDADuloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CAJune 10, 2026
- FDADuloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc.,May 13, 2026
- FDADuloxetine Delayed-Release Capsules, USP, 60mg, Rx Only, 1000-count bottles, Mfr. by: Towa PharmaceuticalMarch 19, 2025
- FDADuloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, Mfr. by: Towa PharmaceuticalMarch 19, 2025
Questions about this recall
Was Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10 recalled?
Yes. FDA published recall D-0270-2025 on March 19, 2025. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DULOXETINE.